CARVEDILOL (carvedilol) by Molecular Devices is β-adrenoreceptor blocking activity is present in the s(-) enantiomer and α 1 -adrenergic blocking activity is present in both r(+) and s(-) enantiomers at equal potency. Approved for mild-to-severe chronic heart failure of ischemic, cardiomyopathic origin, usually in addition to diuretics and 14 more indications. First approved in 2007.
Drug data last refreshed 19h ago
β-adrenoreceptor blocking activity is present in the S(-) enantiomer and α 1 -adrenergic blocking activity is present in both R(+) and S(-) enantiomers at equal potency. Carvedilol has no intrinsic sympathomimetic activity.
Worked on CARVEDILOL at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Effects of Carvedilol on Suppressing the Premature Ventricular Complex/Ventricular Tachycardia From Outflow Tract
Comparative Effects of Nebivolol and Carvedilol on Diastolic Function in the Elderly Heart Failure Patients
Immediate Release Versus Slow Release Carvedilol in Heart Failure
Efficacy and Safety of Carvedilol SR Versus Carvedilol IR in Patients With Essential Hypertension
Pilot Study of the Safety and Efficacy of Carvedilol in Pulmonary Arterial Hypertension